Somebody else pays first: management describes counterparties putting their own money down ahead of delivery
The model's full reasoning — Q4 2022 call → NOWe need answer only YES or NO. Need analyze transcript. Question: Does management describe that counterparties are putting their own money/resources at risk before receiving what they pay for — pre-funding company? Need see if management conveys actual advance commitments from customers/partners, not financing. In transcript, there is mention of partnerships, milestones, Royalty Pharma sale. But Royalty Pharma is financing/monetization, not commercial counterparty pre-funding for goods/services? Also Takeda collaboration revenue recognized as performance obligations, but that's standard collaboration upfront payments? Need assess. Question specifically: "people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for — paying, depositing, reserving, funding, or committing capital in advance of delivery — and does management present this as something actually happening now in real dealings rather than as a hope, a plan, or an industry norm the company has always enjoyed?" Need look for management describing counterparties pre-funding. In transcript, Chris mentions "We currently have partnerships with five different companies and we expect to receive milestone payments from each over the next 12 months." That's future expected, not necessarily pre-funding. Also "we recently decided to sell the potential royalties we would receive from Amgen on future olpasiran sales to Royalty Pharma. We received $250 million in cash upfront..." That's selling royalty rights, a financing transaction, not counterparty pre-funding for company's products. Also "Takeda submitted Phase 3 protocol... waiting feedback" no. Revenue recognition: Ken says "Revenue for fiscal '22 was $243.2 million... primarily relates to our collaboration agreements with Takeda and Horizon. Revenue will be recognized as we complete our performance obligations, which includes managing the ongoing AAT Phase 2 clinical trials for Takeda, and delivering a Phase 1 ready candidate to Horizon.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| ROP | Roper Technologies, Inc. | Q2 2018 | 2018-07-26 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
SYM · Q3 2022 → YESThe question is: Does management describe that the people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for ...YES The transcript shows management describing real advance commitments from customers: the $11.3 billion backlog (more than doubled), strong deferred revenue on the balance sheet representing a "very significant cost float," and contracts that lock in commitments with restricted changes. Revenue is recognized on a percentage-of-completion basis during deployment, meaning payments 18 months ahead of acceptance. This is framed as an active benefit enabling confident scaling, not a routine or historical norm. They also note improved supplier terms, but the customer-side pre-funding via deferred revenue and backlog is explicitly highlighted as occurring now. This meets the criteria for counterparties committing capital ahead of delivery.
EVGO · Q2 2022 → YESThe question is: Does management describe that the people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for ...YES The transcript shows management describing the eXtend model with Pilot and GM where the customer (Pilot/GM) incurs the upfront capital expenditures for the charging infrastructure, while EVgo receives ongoing revenues from operations, maintenance, and services. This is presented as an actual, current business arrangement that provides EVgo with immediate cash flow and contracted revenues, not as a future hope or industry norm. Cathy Zoi notes the agreement exceeds IRR hurdles and provides near-term revenue, and Olga Shevorenkova explains the customer funds the build-out, enabling EVgo to generate margin as developer and operator.
BLZE · Q3 2022 → YESThe question is: Does management describe that the people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for ...YES The transcript shows management describing B2 Reserve as a capacity-based pricing program that includes premium support and free data migration, with revenue ramping in Q3. Frank notes B2 Reserve contracts are "effectively committed contracts," and Gleb calls them "committed contracts" in response to an investor question. This is presented as occurring now, with "initial ramp in demand" and "revenue increasing each month of Q3," not as a future plan or industry norm. The capacity-reservation aspect aligns with the described phenomenon of counterparties committing capital in advance.